Introduction {#S0001}
============

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that exhibits intravascular hemolysis, thrombosis, and renal dysfunction due to the clonal expansion of hematopoietic stem cells that have acquired mutations in the *phosphatidylinositol glycan class A* gene and increased erythrocyte complement sensitivity.[@CIT0001] Eculizumab (Soliris^®^; Alexion Pharmaceuticals, New Haven, CT, USA); complement component 5-targeted agents, has been developed as a breakthrough treatment for PNH. This drug has been shown not only to reduce hemolysis and prevent thrombosis, but also to improve anemia, renal function, quality of life and patient survival.[@CIT0002] However, it has been reported that its use increases the risk of developing invasive meningococcal infection 1000--2000 times,[@CIT0003] and recently, it was reported that disseminated gonococcal infection (DGI) could occur.[@CIT0004] This condition is rare, but considered an important disease concept. We report here a young patient with PNH using eculizumab who developed DGI.

Case Report {#S0002}
===========

A 22-year-old Japanese male patient with PNH was treated with eculizumab in our department six months prior to this presentation, and eculizumab was given every two weeks thereafter. The patient was injected with Menactra^®^, a quadrivalent meningococcal vaccine against serogroups A, C, Y, and W-135, at the beginning of eculizumab treatment, while prophylactically receiving fluoroquinolones antibacterial agent, levofloxacin, for 6 weeks. Then, he had not taken antibiotics for more than four months and had never been injected with a serogroup B meningococcal vaccine. The patient complained of a high fever of 39.5 °C, mild nausea and headache, and was sent to our department by ambulance. The patient was aware of pain with urination and pyuria the night before. The patient had been given eculizumab one week prior, and at that time, there was no remarkable change in his physical condition; no new drugs, including antibiotics, were prescribed. On admission, laboratory data were as follows: hemoglobin (Hb) 11.5 g/dL (decreased to 8.3 g/dL after 3 days; presumed to be hemolysis after infection), white blood cell count (WBC) 8600/µL (neutrophils 90%), C-reactive protein (CRP) 2.24 (normal range: 0--0.3) mg/dL and LDH 334 (120--245) U/L. Urinalysis showed a WBC of 10--19/high power field in the sediment, but urine culture was negative. Neither cerebrospinal fluid nor synovial fluid collection tests were performed. No abnormalities were found on a CT image (brain - pelvis). Venous blood culture was collected from the bilateral upper limbs, and 2 g of ceftriaxone (CTRX) was administered twice per day (total: 4 g). Thereafter, *Neisseria gonorrhoeae* was detected in cultures, and our case was diagnosed as DGI. CTRX was administered for 8 days beginning from the day of hospitalization. His subjective symptoms and physical condition immediately improved, and laboratory data other than anemia were generally normalized. The patient was discharged.

His sexual partner (female) was also found to have gonococcal infection and was treated at another clinic. He had no history of sexually transmitted disease, and it was unknown when she became infected with gonorrhea. Both had no habit of having unusual sex, such as exchange sex, or sex with multiple partners. After discharge, they performed several sexual acts but did not strictly wear condoms. Four weeks after the previous discharge, the patient received eculizumab twice, complained of high fever (39.5°C), mild nausea, neck-occipital pain, and left femoral pain and was urgently admitted again. The patient was not aware of urethritis symptoms at this presentation. Laboratory data showed Hb 11.0 g/dL (decreased to 8.1 g/dL after 3 days), WBC 11,500/µL (neutrophils 85%), CRP 3.69 mg/dL, and LDH 285 U/L. Gonococcus presence was proven again in a venous blood culture. Similar to the last presentation, CTRX was administered at a daily total dose of 4 g divided into two doses for 8 days. Both his general condition and data improved early on, and he was discharged. The patient was counseled several times on safer sexual activity, including accurate and consistent use of condoms, by urologist. He was also prescribed by his urologist sultamicillin tosylate (750 mg/day), which was sensitive to this gonococcus, for one month. The patient eventually discontinued his relationship and was no longer a sexual partner. Since then, DGI has not recurred for more than 1 year, and his PNH has a stable clinical course.

Discussion {#S0003}
==========

Eculizumab binds to the complement protein C5 and inhibits the release of C5a, as well as the production of the terminal membrane attack complex (MAC) C5b-C9 following C5b, thereby significantly limiting complement activity.[@CIT0005] For this reason, eculizumab is a very useful drug for PNH with dysregulation of complement activation, but the drug inhibits MAC formation and prevents efficient serum bactericidal activity.[@CIT0006] It has been confirmed that treatment with eculizumab is likely to result in serious infections with *Neisseria* species, including *N. meningitides*.[@CIT0003],[@CIT0007],[@CIT0008] Patients with infections caused by *N. sicca/subflava* have also been observed; these organisms are considered nonpathogenic.[@CIT0009]

Gonococci are a gram-negative bacilli belonging to the *Neisseria* species and have 70% DNA homology with meningococci. DGI is a rare condition that occurs in only 1 to 3% of all patients with gonococcal infection, and it occurs more frequently in women;[@CIT0010] complement deficiency has long been reported to be a risk factor.[@CIT0011] Recently, several cases of DGI associated with eculizumab were reported successively,[@CIT0012]--[@CIT0014] and in a recent review, 8 of 9 patients were women who were highly sexually active.[@CIT0004] Nine of 11 patients with DGI reported from Japan before eculizumab use was launched were male.[@CIT0015] The reason for this sex difference between Japan and other Western countries is unknown.

In our young male patients with PNH, bacteremia and arthritis-like signs developed rapidly within just 12 hours after he became aware of urethritis symptoms. In a recent review of DGI with eculizumab,[@CIT0004] 3 out of 9 patients were reported to develop dangerous and life-threatening general conditions, and one of those patients died. We used rapid and high-dose CTRX based on an invasive meningococcal infection in accordance with the guidelines of the Japanese Society for Neuroinfectious Diseases.[@CIT0016] The general condition of the patient improved quickly, and he was able to return to his daily life. However, DGI redeveloped repeatedly within a short period of time. The source and route of the two gonococcal infections were truly unknown. According to their statements, with regard to the initial infection, his partner may have previously been affected without awareness. It was not clear whether the second DGI was a new infection or whether some of the bacteria survived after the first sepsis presentation. Our patient had meningitis-like symptoms when he developed DGI. The treatment of DGI recommended by the Japanese Society for Sexually Transmitted Infections guidelines is to administer 1.0 g of CTRX intravenously 1 time/day for 3--7 days.[@CIT0017] In contrast, the recommended US Centers for Disease Control and Prevention regimen for DGI manifesting as gonococcal meningitis requires 1--2 g of CTRX intravenously every 12--24 hours for 10--14 days.[@CIT0018] The first-line drug of severe infection, whether gonococcal or meningococcal, is currently considered to be CTRX. Regarding the optimal period of CTRX treatment (4 g/day), it recurred for 8 days of medication in this time, so it was thought that about 10 days would be suitable. In the future, it is necessary to establish the dosage and duration of intravenous CTRX for DGI in patients taking eculizumab.

In considering the preventive measures, we should explain to partner as well as the patient that young PNH patients using eculizumab are at risk of developing DGI, while checking whether both are infected with *N. gonorrhoeae*. In addition, we should educate them on regular use of condoms including during oral sex. Meanwhile, Petousis-Harris et al recently reported that it has been suggested that vaccination against group B Neisseria meningitidis may reduce the risk of gonococcal infection.[@CIT0019] In Japan, Menactra^®^ was finally approved in 2015, but until now (July 2020), the serogroup B meningococcal vaccine has not yet been approved and we did not administer to this patient. The group B meningococcal vaccine should be approved as soon as possible in Japan, as in Western countries.

In conclusion, to our knowledge, this study is the first case report of DGI that developed in a Japanese patient with PNH receiving eculizumab. Although gonococcal infections rarely develop into DGI, hematologists and infectious disease specialists need to recognize that the risk is increased for patients with PNH receiving eculizumab. When serious signs of infection occur, it is recommended to consider DGI as well as invasive meningococcal infection as a differential diagnosis, and intravenous CTRX should be given early.
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